Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder

CONCLUSION: Six targeted and immunotherapeutic agents have been approved for patients with advanced urothelial bladder cancer. They all have demonstrated activity in patients for whom disease has progressed during or after platinum-based therapy. Pembrolizumab, with and without enfortumab, has demonstrated first-line activity, and avelumab is a key maintenance therapy after first-line treatment. The results of additional clinical trials should provide evidence to establish the exact role in therapy of each agent in patients with advanced disease.PMID:38679913 | DOI:10.1093/ajhp/zxae090
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Source Type: research